Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial Authors: Glenn Hamonic, Supriya Arora, Ravendra Garg, Erin Scruten, Rachelle Buchanan, Stephanie L. Saundh, Nicolas Collin, Stephen Sanche, Noah Vale, Timothy Salter, Scott A. Halperin, Joanne M. Langley, Volker Gerdts, Trina Racine Published: 2026 ABSTRACT ABSTRACTThis Phase 1 clinical trial evaluated the safety and immunogenicity of COVAC-2, a recombinant protein subunit vaccine as a heterologous booster in adults previously immunized with authorized COVID-19 vaccines (NCT05226702). COVAC-2 contains the SARS-CoV-2 S1 spike protein subunit adjuvanted with Sepivac SWE™, an open-access oil-in-water adjuvant. Sixty participants were randomized to receive a single intramuscular dose of COVAC-2 (10 µg or 25 µg) or placebo, with follow-up through Day 180. The vaccine was well tolerated, with most adverse events being mild or moderate; no serious adverse events were attributed to vaccination. Immunogenicity assessments included spike-binding antibody ELISA, pseudovirus neutralization assays (PNA), ELISpot, and flow cytometry. The 25 µg dose elicited the strongest humoral and cellular responses, with peak antibody titers observed 14 d after COVAC-2 vaccination. While titers waned, they were sustained above baseline through Day 180. ELISpot and flow cytometry revealed elevated IFN-γ and IL-2 responses indicating antigen-specific T-cell activation. Minimal IL-4 and IL-13 responses were demonstrated by flow cytometry. These findings support the safety and immunogenicity of COVAC-2 as a heterologous booster, particularly at the 25 µg dose level. The favorable safety profile, induction of immune responses, and thermal stability of the vaccine formulation suggest its potential utility in global vaccination strategies, especially in low- and middle-income countries. COVAC-2 may offer a scalable and accessible platform for enhancing protection against COVID-19.Clinicaltrials.gov: NCT05226702 – Registered 22 Jul 2022 Introduction Since its emergence in late 2019, the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in over 7 million deaths worldwide and continues to pose a significant global health threat.1 The continual emergence of new viral variants has led to periodic surges in infection rates, underscoring the ongoing need for vigilance and sustained vaccination efforts particularly in high-risk persons. Numerous studies have demonstrated that high vaccination coverage and booster doses during periods of risk are associated with reduced rates of hospitalization and mortality.2 However, despite rapid advancements in vaccine development, equitable global access to COVID-19 vaccines remains a persistent challenge.3 The impact of the pandemic varied significantly across countries, with socioeconomic status (SES) emerging as a key determinant of health outcomes. Populations with lower SES have experienced lower vaccination coverage, resulting in disproportionately higher rates of infection and mortality.4 These disparities are thought to be due to unequal access, vaccine hesitancy and logistical barriers to delivery and uptake, particularly in low- and middle-income countries (LMICs). To address these challenges, the Vaccine and Infectious Disease Organization (VIDO), at the University of Saskatchewan, developed COVAC-2, a recombinant protein subunit vaccine containing the S1 region of the SARS-CoV-2 spike protein, including the receptor-binding domain (RBD). COVAC-2 is formulated with Sepivac SWE™ (SWE), a squalene-based oil-in-water emulsion adjuvant of similar composition to that of MF59®, composed of squalene and two surfactants, polysorbate 80 and sorbitan trioleate, but without the additional lipid, α-tocopherol (Vitamin E), found within AS03™.5 Immunologically, SWE has been shown to induce responses comparable to MF59®, inducing balanced Th1/Th2 immune profiles and enhancing antibody titers, including robust neutralizing responses when formulated with recombinant protein antigens,6,7 and demonstrating dose sparing.8 SWE, co-developed by the Vaccine Formulation Institute (VFI) and Seppic, is the first GMP grade oil-in-water adjuvant made available under an open-access model at large-scale, enabling broad accessibility for vaccine developers. Protein subunit vaccines such as COVAC-2 are known for their favorable safety profiles, cost-effectiveness, and thermal stability, making them particularly well-suited for use in regions with limited cold-chain infrastructure.9,10 Several protein-based COVID-19 vaccines similar to COVAC-2 have achieved Emergency Use Authorization, demonstrating the feasibility of this platform playing a role in the COVID-19 response. Examples include, NVX-CoV2373, a full-length prefusion spike nanoparticle formulated with saponin-based Matrix-M™,11 ZF2001, a dimeric RBD-only antigen formulated with a conventional alum adjuvant delivered in a three-dose primary series,12 and MVC-COV1901, which employs a prefusion-stabilized full spike (S-2P) formulated with two adjuvants, CpG1018 and aluminum hydroxide.13,14 Some of these other recombinant protein vaccines have also demonstrated success as heterologous boosters.15,16 The first-in-humans trial of COVAC-2, a randomized, placebo-controlled, dose-escalation study in healthy adults aged 18–54 and 55+ evaluated low, medium, and high dose levels and demonstrated its safety and immunogenicity.17 As the global vaccination and infection landscape evolved, this study was initiated to evaluate the potential of COVAC-2 as a heterologous booster in individuals previously immunized with authorized COVID-19 vaccines. We aimed to assess if this oil-in-water adjuvanted protein-based COVID-19 vaccine was safe, boosted existing immune responses, and the nature and durability of these responses in adults who had received at least two prior authorized COVID-19 vaccine doses. Materials and methods Study design This Phase 1 study was a randomized, placebo-controlled, observer-blinded clinical trial conducted across multiple centers to assess the safety profile and immune response generated by a single booster administration of a SARS-CoV-2 vaccine (Figure 1). Participant allocation was stratified based on age category as well as the number of prior COVID-19 vaccine doses received. Figure 1.CONSORT flow diagram.The CONSORT flow diagram shows a clinical trial process. Initially, 79 participants were assessed for eligibility. Of these, 19 were excluded: 15 did not meet inclusion criteria and 4 were excluded due to randomization closure. Sixty participants were randomized into three groups: 19 allocated to a 10 microgram dose, 22 to a 25 microgram dose and 19 to a placebo. All participants in each group received their respective doses. In the 10 microgram group, 2 withdrew consent, with none lost to follow-up, resulting in 19 analyzed for the primary outcome. In the 25 microgram group, 2 withdrew consent and 1 was lost to follow-up, resulting in 21 analyzed, with 1 excluded from analysis. In the placebo group, none withdrew consent and 1 was lost to follow-up, resulting in 19 analyzed for the primary outcome. A note indicates one participant withdrew consent during a Day 2 phone call, with no safety or immunological data collected and was not included in the safety analysis.CONSORT flow diagram of a clinical trial with 79 participants assessed for eligibility. CONSORT flow diagram. The trial (ClinicalTrials.gov identifier: NCT05226702) was carried out in accordance with Good Clinical Practice standards, the ethical principles of the Declaration of Helsinki, and all relevant national regulatory requirements. Approval for the study protocol was obtained from institutional review boards at each participating site, including the IWK Health Research Ethics Board (Project #1027723), the University of Saskatchewan Biomedical Research Ethics Board (Bio-REB 3827), and the Advarra Research Ethics Board (SSU00188255 and SSU00188257). Oversight was provided by an independent Data Safety Monitoring Board, which reviewed safety data at predefined intervals throughout the study. Enrollment began on August 16, 2022, and the final participant visit occurred on November 13, 2023. Participants Adults were recruited after providing informed consent at one of four clinical sites across Canada: Halifax, Nova Scotia; Toronto, Ontario; Burlington, Ontario; and Saskatoon, Saskatchewan. Individuals were eligible for enrollment if they were at least 18 y old, generally healthy, and had previously received two or more doses of an authorized COVID-19 vaccine, with the most recent dose administered a minimum of four months before study entry. Participants were also required to use reliable contraception beginning 30 d prior to vaccination and continuing for 180 d afterward. Female participants had to undergo pregnancy testing on the day of vaccination and test negative to proceed. Participants were excluded if they had received any non-COVID-19 licensed vaccine–such as a seasonal influenza vaccine–within two weeks of the study injection, or if they had recently been exposed to an investigational SARS-CoV-2 vaccine or had a confirmed SARS-CoV-2 infection within the preceding four months. Additional exclusion criteria included recent treatment with blood products or another investigational drug, known allergies to any component of the study vaccine, conditions associated with immune suppression, coagulation disorders, autoimmune diseases, malignancy, or any other clinically relevant abnormalities identified through medical history, physical examination, or laboratory assessments (hematology, biochemistry, and urinalysis). Women who were pregnant or breastfeeding were not eligible to participate. Study vaccine The investigational vaccine consisted of a recombinant SARS-CoV-2 S1 subunit protein formulated with the squalene-based oil-in-water adjuvant Sepivac SWE™. All vaccine components were manufactured, vialed, and stored as described in Hamonic et al.17 While the GMP manufactured lots of Sepivac SWE™ and PBS diluent used in this study were the same as in Hamonic et al.17 the S1 antigen lots differed (Lot # D03580RDA, D03552RDB and D03582RDA). Just before the study injection was given, the S1 protein solution was adjusted to the required concentration and then mixed in equal volumes with the SWE adjuvant. This preparation produced a 0.5 mL dose containing either 10 µg or 25 µg of the S1 antigen. Participants assigned to the control arm received sterile normal saline. All study injections–both vaccine and placebo–were prepared and administered exclusively by unblinded site personnel, who were not involved in any other study activities to preserve the integrity of the blinding. Study procedures Following the consent process, participants underwent eligibility confirmation, which included a review of medical history, a physical examination, and laboratory testing. Screening samples were obtained for hematology, clinical chemistry, pregnancy testing, and baseline serological assessments. Individuals meeting all criteria were scheduled for their initial study visit within 30 d of screening. Group assignments were carried out using a computer-generated randomization schedule specific to each study step (Figure 1). Participants were randomized in a 1:1:1 ratio to receive either 10 µg COVAC-2, 25 µg COVAC-2, or placebo. Randomization was stratified by age category (18–54 y vs. ≥55 y) and by the number of previously administered COVID-19 vaccine doses. Each participant received a single intramuscular injection into the deltoid muscle and was monitored through Day 180. Safety assessments included collection of solicited local and systemic adverse events (AEs) for 7 d after vaccination, while unsolicited AEs were documented for 28 d. Serious adverse events (SAEs), medically attended events (MAEs), potential immune-mediated conditions (pIMDs), and any COVID-19–related illness were captured throughout the 180-day follow-up period. Blood samples for hematology and biochemistry were obtained during screening and again on Days 7, 14, and 28. Pregnancy testing using blood or urine was performed both at screening and immediately prior to dosing on Day 0. Serum samples were collected before vaccination on Day 0 and subsequently on Days 7, 14, 28, 90, and 180 for evaluation of binding and pseudovirus-neutralizing antibody responses. Peripheral blood mononuclear cells (PBMCs) were isolated on Days 0, 7, 14, 28, and 180 to characterize vaccine-induced cell-mediated immune responses. Outcome measurement Safety and reactogenicity The primary objective was to evaluate the safety of the COVAC-2 vaccine (10 or 25 μg dosing of S1 antigen adjuvanted with SWE) in healthy adults aged 18 and above. Safety and reactogenicity were recorded, classified and graded as described in Hamonic et al.17 Briefly, at the Day 0 vaccination visit, participants were trained to use diary cards to record solicited local and systemic AEs, as well as any concomitant medications, for the first 7 d following injection. They were also instructed to document unsolicited AEs for 28 d. During each subsequent study visit, participants were asked about any new or ongoing health concerns. Any AEs still present on Day 7 were followed until they resolved. Throughout the entire study period, SAEs, MAEs, pIMDs, and any episodes of COVID-19 were systematically documented. Unsolicited AEs were categorized using the Medical Dictionary for Regulatory Activities (MedDRA). Laboratory abnormalities were graded according to U.S. FDA guidance.18 Immunogenicity The secondary objectives of the study were to determine spike-binding, neutralizing antibody, and cellular immune responses induced by COVAC-2. All immunogenicity outcomes were performed without knowledge of study group allocation. Binding antibodies An enzyme-linked immunosorbent assay (ELISA) was used (IQVIA, Laval, QC) to quantify anti-SARS-CoV-2 Pre-Spike IgG antibodies in human serum samples. A 96-well microplate was coated with recombinant SARS-CoV-2 Pre-Spike antigen (Wuhan-Hu-1 strain; GenBank accession MN908947.3), followed by a blocking step to prevent non-specific binding. Reference standards, controls, and diluted serum samples were then added to the wells, allowing specific IgG antibodies to bind to the immobilized antigen. After washing to remove unbound components, a horseradish peroxidase (HRP)-conjugated anti-human IgG secondary antibody was introduced to detect the bound primary antibodies. The enzymatic reaction was initiated by the addition of tetramethylbenzidine (TMB) substrate, resulting in a colorimetric change proportional to the concentration of anti-SARS-CoV-2 Pre-Spike IgG antibodies. The reaction was terminated with 2N sulfuric acid, and absorbance was measured at 450/620 nm using a microplate spectrophotometer. The optical density values obtained were directly correlated with antibody concentrations in the samples and initially reported as ELISA Laboratory Units per milliliter (ELU/mL). Using a correlation factor provided by IQVIA, the binding antibody titer was converted to the standardized unit of Binding Antibody Units per milliliter (BAU/mL). Pseudovirus neutralization The SARS-CoV-2 Pseudotyped Virus Neutralization Assay (PNA) was used at IQVIA (Laval, QC) to assess the levels of neutralizing antibodies against SARS-CoV-2 in human serum samples. Pseudotyped viral particles were generated using a modified Vesicular Stomatitis Virus (VSVΔG) backbone expressing the SARS-CoV-2 spike glycoprotein (Wuhan-Hu-1 strain; GenBank accession MN908947.3), in which the C-terminal 19 amino acids of the cytoplasmic tail were deleted. These pseudoviruses also incorporated a luciferase reporter gene to enable quantification of infection. Heat-inactivated serum samples were subjected to seven two-fold serial dilutions in 96-well transfer plates. The SARS-CoV-2 pseudovirus was added to each dilution at a defined working concentration and incubated at 37°C with 5% CO2 to allow antibody-virus interaction. The resulting serum-virus mixtures were then transferred to 96-well plates pre-seeded with Vero E6 cells and incubated under the same conditions. Following incubation, luciferase substrate was added and luminescence was measured using a plate reader. The luminescence signal, expressed in relative luminescence units (RLU), was inversely proportional to the concentration of neutralizing antibodies in the serum. The neutralizing antibody titer was initially determined as the reciprocal of the serum dilution that achieved 50% inhibition of pseudovirus infection (NT50) and then converted to International Units per milliliter (IU/mL) using a correlation factor provided by IQVIA. ELISpot IQVIA conducted the ELISpot assay, as described in Hamonic et al.17 and Manak et al.19 Briefly, interferon gamma (IFNγ) and interleukin-5 (IL-5)-producing cells were quantified in PBMCs stimulated with SARS-CoV-2 S peptide pools (JPT PM-WCPV-S-2) using a human IFNγ/IL-5 double-color enzyme-linked immunosorbent spot (ELISpot) kit (Cellular Technologies) in a qualified assay. Intracellular cytokine analysis by flow cytometry Intracellular cytokine analysis was carried out by CIRION (a Cerba Research Company, Laval, QC) on PBMCs for assessment of the cell mediated immune response. Frozen PBMCs were thawed, washed and plated at 10 × 105 cells/well in a 96 well plate, plated in duplicate per stimulation. Cells were stimulated with PepTivator SARS-CoV-2 Prot_S Complete (Premium grade, Miltenyi Biotec; GenBank MN908947.3), Media (containing sterile water to the equivalent of the Peptivator stimulation), and PMA/Ionomycin. Cells were incubated for 16–20 hours at 37°C prior to the addition of GolgiPlug and GolgiStop (BD Bioscience) followed by an additional 6-hour incubation at 37°C. Stimulated cells were stained with stain panel 1 (see Table 1) including the Fixable Viability Stain 780 (BD Biosciences) in staining buffer (DPBS with 2% FBS) for 30 minutes at 5.0°C and then cells were fixed and permeabilized in the BD Cytofix/Cytoperm™ Fixation/Permeabilization Kit (BD Biosciences) for 25 minutes at 5.0°C. After a wash (BD Perm/Wash Buffer), cells were stained with stain panel 2 (Table 1) in wash buffer for 30 minutes at 5.0°C. Cells were finally suspended in wash buffer and transferred to labeled round bottom tubes for flow cytometry analysis the next day. A BD FACSCanto™ II with BD FACSDiva Software version 9.2 was used for data capture and interpretation.Table 1.Antibodies used in flow cytometry analysis.TargetStain panelFluorochromeCloneSupplierCD41APCSK3BD BioscienceCD81V500SK1BD BioscienceCD32FITCHIT3αBD BioscienceIFN-ɣ2BV421B27BD BioscienceIL-22BB700MQ1–17H12BD BioscienceIL-42RB780MP4–25D2BD BioscienceIL-132PEJES10–5A2BD Bioscience Table 1.Antibodies used in flow cytometry analysis.TargetStain panelFluorochromeCloneSupplierCD41APCSK3BD BioscienceCD81V500SK1BD BioscienceCD32FITCHIT3αBD BioscienceIFN-ɣ2BV421B27BD BioscienceIL-22BB700MQ1–17H12BD BioscienceIL-42RB780MP4–25D2BD BioscienceIL-132PEJES10–5A2BD Bioscience Antibodies used in flow cytometry analysis. CD4+ cells (CD4+CD8−) and CD8+ cells (CD4−CD8+) were gated on live singlet lymphoid CD3+ cells and analyzed for expression of IFN-γ, IL-2, IL-4, and IL-13, expressed as a percentage of the parent populations. Sample size and statistical analysis Because the primary endpoint focused on evaluating safety, the number of participants was determined by estimating the likelihood of observing at least one AE within each study arm. With groups of 20 individuals receiving COVAC-2, the study design allowed detection of an AE rate of 10% or higher with a probability greater than 0.88. When considering all 40 recipients of COVAC-2 across dose levels, an AE rate of 5% or more could be identified with a probability exceeding 0.87. Safety analyses were conducted using the Total Vaccinated Cohort (TVC), which included all randomized participants who received any study injection. Participants were evaluated according to the treatment they received. Immunogenicity outcomes were assessed in both the Intent-to-Treat (ITT) population–defined as all members of the TVC with available immunological data–and the Per-Protocol (PP) population, which consisted of ITT participants who satisfied all eligibility requirements and had no protocol deviations affecting immunogenicity assessments. The PP dataset excluded samples collected after receipt of authorized COVID-19 vaccines or prohibited medications, as well as results that did not meet predefined laboratory quality criteria (e.g., low PBMC viability or invalid assay controls). For all immunological endpoints, geometric mean values and corresponding 95% confidence intervals were calculated by study group using the PP population. Significant differences were determined analyzing log transformed data by mixed-effects model and Geisser-Greenhouse correction, with Dunnett’s multiple comparison test comparing values within each dose range back to Day 0. Geometric mean fold rise (GMFR) values for ELISA and PNA were calculated first by determining the fold rise of each participant, at each timepoint, compared to their Day 0 titer, then calculating the geometric mean for that overall timepoint. Missing observations were omitted, and no imputation procedures were applied. Although subgroup analyses were planned to compare ELISA and pseudoneutralization antibody titers by prior number of COVID-19 vaccinations and type of previous vaccine, these exploratory evaluations were not performed because only one of the predefined subgroups contained the minimum of 10 participants required for meaningful interpretation. Results The demographics for all participants at enrollment and number of prior COVID-19 vaccines are summarized in Table 2. Briefly, of 79 individuals screened, 60 were eligible, randomized and received one injection. A higher proportion of females (63.3%) than males (36.7%) participated. The mean age was 44.0 y (range: 19–69), and the majority identified as White (66.7%), followed by Asian (18.3%), Black or African American (5.0%), and Other (10.0%). The mean body mass index (BMI) was 29.2 kg/m2 (±7.6), with a mean height of 1.7 m (±0.09) and mean weight of 83.7 kg (±24.8). Participants were randomized into three groups: 10 µg (n = 19), 25 µg (n = 22), and placebo (n = 19). Demographic distributions were balanced across groups. Among female participants, 55.3% were of childbearing potential.Table 2.Demographics and baseline characteristics of participants by study group. 10 µg25 µgPlaceboAllParticipants in population19221960Sex; No. (%)Male7 (36.8)7 (31.8)8 (42.1)22 (36.7)Female12 (63.2)15 (68.2)11 (57.9)38 (63.3)AgeMean43.744.743.444SD15.7713.914.4514.44Range19–6919–6923–6719–69BMI (kg/m2)Mean28.428.530.729.2SD8.895.958.067.6Range18.7–57.419.6–43.719.1–47.718.7–57.4Race; No. (%)Asian4 (21.1)4 (18.2)3 (15.8)11 (18.3)Black or AfricanAmerican2 (10.5)1 (4.5)0 (0.0)3 (5.0)White12 (63.2)14 (63.6)14 (73.7)40 (66.7)Other1 (5.3)3 (13.6)2 (10.5)6 (10.0) Table 2.Demographics and baseline characteristics of participants by study group. 10 µg25 µgPlaceboAllParticipants in population19221960Sex; No. (%)Male7 (36.8)7 (31.8)8 (42.1)22 (36.7)Female12 (63.2)15 (68.2)11 (57.9)38 (63.3)AgeMean43.744.743.444SD15.7713.914.4514.44Range19–6919–6923–6719–69BMI (kg/m2)Mean28.428.530.729.2SD8.895.958.067.6Range18.7–57.419.6–43.719.1–47.718.7–57.4Race; No. (%)Asian4 (21.1)4 (18.2)3 (15.8)11 (18.3)Black or AfricanAmerican2 (10.5)1 (4.5)0 (0.0)3 (5.0)White12 (63.2)14 (63.6)14 (73.7)40 (66.7)Other1 (5.3)3 (13.6)2 (10.5)6 (10.0) Demographics and baseline characteristics of participants by study group. Details of allocation, withdrawals and completion are shown in Figure 1. All participants had received at least two prior COVID-19 vaccinations at least 4 months prior to Day 0, with 51.7% having received three doses (Supplemental Table 1). All but three study participants (5%) received one or more doses of an mRNA vaccine prior to study entry (Supplemental Table 1). The time interval between administration of authorized vaccine and study vaccine was initially 6 months and changed to 4 months to improve eligibility. The distribution and type of prior vaccinations was similar across age groups and treatment arms (Supplemental Table 1). Four participants withdrew from the study by Day 180 (2 participants each from the 10 µg group and the 25 µg group), and 2 participants were lost to follow up (1 participant each from the 25 µg group and the placebo group). Safety Solicited local and systemic treatment-emergent adverse events (TEAEs) reported from Days 0 to 6, stratified by study group, are presented in Figure 2. The most reported solicited TEAEs (local and systemic) across all groups were injection site tenderness (36 occurrences, 61.0%) and pain (32 occurrences, 54.2%), followed by drowsiness (16 occurrences, 27.1%), generalized muscle aches (15 occurrences, 25.4%), fatigue (13 occurrences, 22.0%), and headaches (13 occurrences, 22.0%), and were mostly grade 1 and 2 in intensity. Grade 3 events were uncommon, and no grade 4 events occurred. Of the 59 participants analyzed for safety, 41 (69.5%) reported solicited TEAEs in the overall safety population, with most events classified as mild (31 participants, 52.4%), followed by moderate (9 participants, 15.3%) and severe (1 participant, 1.7%). The 25 µg group showed a higher frequency of moderate and severe events. Age-stratified analyses revealed that 29 (70.7%) participants aged 18–54 y and 12 (66.6%) of those aged 55 y and older experienced at least one solicited TEAE regardless of study group. In the younger age group, drowsiness (12 participants, 29.3%), muscle aches (11 participants, 26.8%), and tenderness (24 participants, 58.5%) were most common. Among older participants, tenderness (8 participants, 44.4%) and pain (9 participants, 50.0%) were the most frequently reported local reactions, while systemic events were less frequent but included severe fatigue, headache, and joint pain in the 25 µg group. No SAEs related to COVAC-2 administration occurred. All age-stratified analyses conducted in this study are considered exploratory in nature due to the limited group sizes. Figure 2.Solicited local and general (systemic) reactions in the 7 d following administration of COVAC-2, at each dose level, and placebo.The image A showing General reactions. Horizontal axis label: percent of participants, unit: percent. Range: 0 to 100. Ticks: 0, 20, 40, 60, 80, 100. Vertical categories: Any general reaction; Chills; Diarrhea; Drowsiness; Fatigue; Fever; General muscle aches; Headache; Joint pain; Malaise; Nausea; Vomiting. Each category has three horizontal stacked bars labeled Placebo, 10 ug, 25 ug, with segments labeled Mild, Moderate, Severe. Any general reaction: Placebo about 30 percent total; 10 ug about 45 percent; 25 ug about 65 percent with a small Severe segment. Chills: all near 0 to about 5 percent. Diarrhea: Placebo near 0; 10 ug about 10 percent; 25 ug about 15 percent. Drowsiness: Placebo about 10 percent; 10 ug about 25 percent; 25 ug about 45 percent with a small Severe segment. Fatigue: Placebo about 5 percent; 10 ug about 10 percent; 25 ug about 40 percent with a small Severe segment. Fever: all near 0 to about 5 percent. General muscle aches: Placebo about 10 percent; 10 ug about 20 percent; 25 ug about 50 percent with a small Severe segment. Headache: Placebo about 5 percent; 10 ug about 15 percent; 25 ug about 35 percent with a small Severe segment. Joint pain: Placebo near 0; 10 ug about 10 percent; 25 ug about 25 percent with a small Severe segment. Malaise: Placebo near 0; 10 ug about 20 percent; 25 ug about 25 percent. Nausea: Placebo near 0; 10 ug about 15 percent; 25 ug about 15 percent. Vomiting: 10 ug about 5 percent; 25 ug near 0. The image B showing Local reactions. Horizontal axis label: percent of participants, unit: percent. Range: 0 to 100. Ticks: 0, 20, 40, 60, 80, 100. Vertical categories: Any local reaction; Pain; Redness; Swelling; Tenderness. Each category has three horizontal stacked bars labeled Placebo, 10 ug, 25 ug, with segments labeled Mild, Moderate, Severe. Any local reaction: Placebo about 35 percent; 10 ug about 80 percent; 25 ug about 85 percent with a small Severe segment. Pain: Placebo about 25 percent; 10 ug about 65 percent; 25 ug about 80 percent with a small Severe segment. Redness: Placebo near 0; 10 ug near 0; 25 ug about 10 percent. Swelling: Placebo near 0; 10 ug near 0; 25 ug about 10 percent. Tenderness: Placebo about 25 percent; 10 ug about 80 percent; 25 ug about 85 percent.Two stacked bar charts showing participant percentages for general and local reactions by study group. Solicited local and general (systemic) reactions in the 7 d following administration of COVAC-2, at each dose level, and placebo. Unsolicited TEAEs collected from Days 0 to 27 according to study group are shown in Supplemental Table 2. Headache was the most frequently reported unsolicited TEAE, occurring in 3 participants (5.1%) with a total of 6 events. COVID-19 infections were reported in 3 participants (5.1%), 2 (10.5%) of which were in the 10 μg group and 1 (4.8%) in the 25 μg group. Gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort and respiratory issues such as oropharyngeal pain, productive cough, and rhinorrhea were reported in isolated cases. No serious adverse events or safety concerns were identified during the observation period. Immunogenicity Immune responses to SARS-CoV-2 were detected as early as Day 7 in vaccine recipients across all immunogenicity measures (anti-S binding antibody, PNA, and cellular testing), as shown in Figures 3–5. Figures report the data only from those individuals who followed the protocol (per-protocol), therefore those data points collected after receipt of an authorized COVID-19 vaccine have been removed from Figures 3–5. Figure 3.Immunogenicity based on antigen-specific binding and pseudoneutralizing antibodies against SARS-CoV-2 spike protein measured by ELISA (top row) and PNA (bottom row), respectively, following administration of 2 dose levels (10 and 25 µg) of COVAC-2 or placebo on Day 0. All participants in the PP population are shown in far left plots followed by the 18–54 cohort in the middle and the 55+ y of age on the right. Values plotted represent the geometric mean and error bars represent the 95% confidence intervals. Significant differences were determined analyzing log transformed data by mixed-effects model and Geisser-Greenhouse correction, with Dunnett’s multiple comparison test comparing values within each dose range back to Day 0. BAU/mL = Binding Antibody Unit per milliliter; IU/mL = International Unit per milliliter; GMFR = Geometric Mean Fold Rise.A composite figure with six plots. A) ELISA All. Scatter plot with mean and 95 percent confidence intervals. X-axis: Days Post-Vaccination (Day 0, Day 7, Day 14, Day 28, Day 90, Day 180). Y-axis: BAU per milliliter (GMT plus or minus 95 percent CI), logarithmic ticks at 10 superscript 1 to 10 superscript 5. Three groups: Placebo, 10 microgram, 25 microgram. Points cluster around 10 superscript 3 to 10 superscript 4 across days; dose groups show higher central means than placebo after Day 7. Significance brackets with asterisks appear above dose groups; GMFR values are printed above timepoints. B) ELISA 18-54. Same axes and days as A. BAU per milliliter ranges 10 superscript 1 to 10 superscript 5. Placebo points mostly near 10 superscript 3; 10 microgram and 25 microgram groups show higher means after Day 7 with multiple significance brackets and GMFR labels above. C) ELISA 55 plus. Same axes and days. BAU per milliliter 10 superscript 1 to 10 superscript 5. Fewer points than B; dose groups rise after Day 7 with GMFR labels above; significance brackets appear above some comparisons. D) PNA All. Scatter plot with mean and 95 percent confidence intervals. X-axis: Days Post-Vaccination (Day 0, Day 7, Day 14, Day 28, Day 90, Day 180). Y-axis: IU per milliliter (GMT plus or minus 95 percent CI), logarithmic ticks 10 superscript 1 to 10 superscript 5. Dose groups show higher means than placebo after Day 7; significance brackets and GMFR labels appear above. E) PNA 18-54. Same axes as D. IU per milliliter 10 superscript 1 to 10 superscript 5. Dose groups show increased central means after Day 7 with several significance brackets and GMFR labels. F) PNA 55 plus. Same axes as D. IU per milliliter 10 superscript 1 to 10 superscript 5. Dose groups show modest increases after Day 7; GMFR labels appear above timepoints; fewer significance brackets are shown.Six scatter plots of ELISA and PNA antibody levels over days for placebo and two COVAC-2 doses.Figure 4.Immunogenicity based on T-cell mediated immune responses measured by IFNγ and IL-5 ELISpot following administration of two dose levels (10 and 25 µg) of COVAC-2 or placebo on Day 0. Peripheral blood mononuclear cells (PBMCs) isolated on study Days 0, 7, 14, 28 and 180 were stimulated with one of two SARS-CoV-2 specific peptide pools (Peptide SV1 and Peptide SV2). All participants in the PP population are shown and values plotted represent the geometric mean and error bars represent the 95% confidence intervals.Image A: Scatter plot titled 'IFN gamma Peptide SV1' shows Days Post-Vaccination (Day 0, 7, 14, 28, 180) on the x-axis for Placebo, 10 ug, and 25 ug groups. The y-axis (SFU/10^6 cells) ranges 0-250. Placebo dots range 0-40, with some 160-210. 10 ug dots range 0-70. 25 ug dots range 0-100, with some 120-190. Image B: 'IFN gamma Peptide SV2' plot with similar x-axis. Placebo dots average around 10, with one near 165. 10 ug dots average around 20, with one near 75. 25 ug dots average around 30, with some 120-200. Image C: 'IL-5 Peptide SV1' plot with similar x-axis. The y-axis (SFU/10^6 cells) ranges 0-10. Placebo dots cluster 0-2, with one near 4.5. 10 ug dots cluster 0-2, with some near 6 and 8. 25 ug dots cluster 0-2, with some near 3.5, 7 and 9. Image D: 'IL-5 Peptide SV2' plot with similar x-axis. Placebo dots cluster 0-2, with one near 4.2. 10 ug dots cluster 0-2, with one near 3.7. 25 ug dots cluster 0-2, with dots up to 2.A set of four scatter plots showing ELISpot responses for IFN gamma and IL 5 by peptide pool and dose.Figure 5.Immunogenicity based on T-cell mediated immune responses measured by intracellular cytokine staining for flow cytometry following administration of two dose levels (10 and 25 µg) of COVAC-2 or placebo on Day 0. CD4+ and CD8+ T cells positive for IFN-γ, IL-2, IL-4 and IL-13 after stimulation are shown. All participants in the PP population are shown and values plotted represent the geometric mean and error bars represent the 95% confidence intervals.Image shows eight scatter plots for IFN gamma and IL-5 peptides across age groups 18-54 and 55+ and across peptides SV1 and SV2. The X-axis represents Days Post-Vaccination (0, 7, 14, 28, 180) and the Y-axis shows SFU per 10^6 cells. IFN gamma ranges from 0-250, IL-5 from 0-10. Each plot includes Placebo, 10 microgram and 25 microgram groups with markers and error bars. For IFN gamma: In 18-54, Placebo has a few individuals with high starting titers but otherwise clusters within the 0-50 range, 10 microgram clusters at 0-60 and 25 microgram sees an increase in titers over time peaking at 200-250. In 55+, Placebo is 0-20, 10 microgram peaks at 60 and 25 microgram peaks at 110-150. For IL-5: In 18-54, Placebo is 0-2, 10 microgram peaks at 6 and 25 microgram peaks at 7-9. In 55+, Placebo is 0-1, 10 microgram peaks at 4-9 and 25 microgram is 0-1. IFN gamma peaks are frequent in the 25 microgram group, while IL-5 peaks in the 10 microgram group for 55+ SV1.A set of eight scatter plots showing IFN gamma and IL-5 peptide responses by age, dose and day. Immunogenicity based on antigen-specific binding and pseudoneutralizing antibodies against SARS-CoV-2 spike protein measured by ELISA (top row) and PNA (bottom row), respectively, following administration of 2 dose levels (10 and 25 µg) of COVAC-2 or placebo on Day 0. All participants in the PP population are shown in far left plots followed by the 18–54 cohort in the middle and the 55+ y of age on the right. Values plotted represent the geometric mean and error bars represent the 95% confidence intervals. Significant differences were determined analyzing log transformed data by mixed-effects model and Geisser-Greenhouse correction, with Dunnett’s multiple comparison test comparing values within each dose range back to Day 0. BAU/mL = Binding Antibody Unit per milliliter; IU/mL = International Unit per milliliter; GMFR = Geometric Mean Fold Rise. Immunogenicity based on T-cell mediated immune responses measured by IFNγ and IL-5 ELISpot following administration of two dose levels (10 and 25 µg) of COVAC-2 or placebo on Day 0. Peripheral blood mononuclear cells (PBMCs) isolated on study Days 0, 7, 14, 28 and 180 were stimulated with one of two SARS-CoV-2 specific peptide pools (Peptide SV1 and Peptide SV2). All participants in the PP population are shown and values plotted represent the geometric mean and error bars represent the 95% confidence intervals. Immunogenicity based on T-cell mediated immune responses measured by intracellular cytokine staining for flow cytometry following administration of two dose levels (10 and 25 µg) of COVAC-2 or placebo on Day 0. CD4+ and CD8+ T cells positive for IFN-γ, IL-2, IL-4 and IL-13 after stimulation are shown. All participants in the PP population are shown and values plotted represent the geometric mean and error bars represent the 95% confidence intervals. Participants in the 25 µg group showed the most robust antibody responses. Geometric mean ELISA values in this group rose significantly from baseline (Day 0) to Day 28, attaining a GMT of 6,063 BAU/mL on Day 14, before gradually declining and remaining above baseline out to Day 180. PNA titers for the 25 µg group followed a similar trend, significantly increasing from baseline (Day 0) to Day 28, attaining a GMT of 3,133 IU/mL on Day 14, and then gradually declining but remaining above baseline at Day 180. The 10 µg group also demonstrated strong immunogenicity, with geometric mean values for both the ELISA and PNA assays rising from Day 0, peaking on Day 14 (5,721 BAU/mL and 2,333 IU/mL, respectively) and slowly decreasing to Day 180 all the while remaining above baseline. Placebo recipients showed minimal changes in both ELISA and PNA values over time, with most measurements remaining near baseline levels. When broken out by age group, only the 18–54 age group demonstrated statistically significant increase in ELISA and PNA titers from Day 0 to Day 28. The highest geometric mean fold rise (GMFR) in titers was observed in the 25 µg group for both ELISA and PNA, with fold rise peaking at Day 14 (2.8 and 3.6 GMFR, respectively). Furthermore, the 25 µg 18–54 age group experienced a ≥4-fold rise in PNA titers from Day 14 to Day 90 (Figure 3). Longitudinal analysis of individual ELISA antibody titers revealed distinct immunogenicity profiles across treatment groups. In the placebo group, 7 participants (36.8%) exhibited unexpected increases in antibody titers at Day 90 or 180, likely attributable to natural SARS-CoV-2 infection or receipt of additional COVID-19 vaccination (one participant was confirmed to have received an authorized vaccine on Day 57). However, no further testing was conducted to verify these events. The remaining 12 participants (63.2%) in the placebo group concluded the study with titers below baseline levels. The 25 µg group demonstrated the most consistent increase in antibody titer. Five participants (22.7%) showed titer spikes at Day 90 or Day 180. One spike was associated with an authorized vaccine administered on Day 58, while the other 4 remained unexplained. Seven participants (31.8%) ended the study with titers above baseline, and another 7 (31.8%) had titers that were equal to or lower than their baseline values. The 10 µg group exhibited intermediate immunogenicity. Four participants (21.1%) experienced unexpected titer spikes at Day 90 or Day 180, two of which were linked to authorized vaccinations on Days 28 and 29 and two were unexplained. Five participants (26.3%) concluded the study with elevated titers, while 8 (42.1%) had titers equal to or below baseline. PNA data corroborated the ELISA findings, demonstrating consistent patterns of immune response across treatment groups. T-cell mediated immune responses were assessed by IFN-γ and IL-5 ELISpot stimulated with two SARS-CoV-2 spike specific peptide pools, SV1 and SV2, (Figure 4). The region covered in peptide pool SV1 is found within the vaccine, while the region covered in peptide pool SV2 is not. For IFN-γ, the placebo group showed consistently low responses across all visits and stimulations, indicating minimal antigen-specific T-cell activation. Against peptide pool SV1, which contains the S1 region, the 10 µg group exhibited modest increases, particularly at Days 7 and 14, but by Day 28, IFN-γ levels returned to baseline. The 25 µg group demonstrated the strongest and most consistent IFN-γ responses, with peak values at Day 7. Although responses declined by Day 180, they remained detectable and above those of the 10 µg and placebo groups at the Day 180 timepoint. For IL-5, responses to peptide pool SV1 were generally low across all groups. The placebo group showed negligible activity, while a couple of individuals within the 10 µg group had an IL-5 response. The 25 µg group showed slightly higher IL-5 responses, with some transient increases at Days 7 and 14, but overall levels remained modest. When broken out by age group, some individuals in the 18–54 year old cohort in the 25 µg group experienced a modest response to IFN-γ and IL-5 at Days 7 and 14 to peptide pool SV1, whereas no response was observed in any of the 55+ groups (Supplemental Figure 1). Stimulation with peptide pool SV2 did not stimulate IFN-γ nor IL-5 in any of the groups at any time point, which is consistent with the study vaccine not containing this peptide sequence. Overall, the 25 µg dose elicited the most robust IFN-γ responses and exhibited a minimal IL-5 response. The placebo group showed minimal immune activation, and the time course of responses peaked around Day 7 to 14, declining by Day 180. During flow cytometry analysis, Peptivator-stimulated CD4+ T cells consistently induced higher cytokine (IFN-γ, IL-2 and IL-4) expression compared to baseline on Day 0 (Figure 5). Peak responses were typically observed at Day 7, with a decline by Day 14. In contrast, IL-13 expression was more variable across the samples and generally lower in magnitude. Participants who received the 25 µg dose exhibited significantly higher IFN-γ cytokine response following Peptivator stimulation on study Day 7, compared to baseline levels (Figure 5), indicating robust antigen-specific CD4+ T cell activation. The 10 µg dose group showed weak and inconsistent cytokine expression, suggesting a suboptimal immune response at the lower dose. Antigen-specific CD8+ T cells in the 25 µg group dose demonstrated a significant increase in IFN-γ expression on Day 7 compared to baseline (Figure 5). IL-2, IL-4, and IL-13 cytokine responses were low and variable, limiting meaningful interpretation over the observation period. Background-subtracted (Peptivator minus media control) values provided evidence of antigen-specific T-cell activation in many cases. However, missing data were frequently observed, particularly at later visits, primarily due to insufficient or compromised cellular material for reliable analysis. Placebo recipients showed minimal cytokine induction across all assessed time points. Discussion The COVAC-2 vaccine, a recombinant protein subunit candidate, was developed as part of a broader effort to expand global access to safe and effective COVID-19 vaccines. Building on the first-in-humans trial,17 this follow-up study was designed to assess the vaccine’s potential as a heterologous booster. The rationale for this approach stemmed from the favorable safety profile of protein subunit vaccines, their ease of manufacture, and their suitability for distribution in LMICs due to less stringent cold chain requirements compared to mRNA-LNP vaccines. This approach also reflects growing interest in mixed-platform booster strategies, which may enhance immune responses and extend protection.15,20–22 The 25 µg dose was selected for this study based on the favorable safety and immunogenicity profile observed in the first-in-humans study conducted previously,17 while the 10 µg dose was included as a dose sparing initiative with the hypothesis that a lower dose may be sufficient to induce significant responses in individuals with pre-existing immunity. Overall, the safety profile of COVAC-2 when administered as a booster was favorable, with similar levels of solicited AEs in the seven days post-vaccination as those observed for other mixed platform booster studies conducted.23,24 While the 25 µg group reported a higher frequency of moderate and severe AEs compared to the 10 µg and placebo groups, there was a similar incidence of AEs observed in the 10 and 25 µg groups. Participants exhibited a wide range of pre-existing immunity, which introduced variability in baseline immune responses and complicated interpretation of post-boost immunogenicity. In addition, the source of pre-existing immunity–whether from vaccination, prior infection, or both (hybrid immunity)–was not explicitly determined at study entry, precluding assessment of whether prior infection contributed to elevated antibody titers, as observed by.15 Despite these challenges, the study generated valuable insights into the cellular and humoral responses elicited by COVAC-2. Cellular immune responses were assessed using ELISpot and flow cytometry. The ELISpot assay revealed that IFN-γ responses were most pronounced in the 25 µg group, with peak activity observed between Days 7 and 14 post-vaccination (Figure 4). Although these responses declined by Day 180, they remained detectable in a subset of participants, indicating a degree of immunological persistence. IL-5 responses remained consistently low across all groups and time points, which could have been due to individual baseline immune states being less predisposed to producing IL-5 25 or IL-5 being transiently expressed at time points not obtained in the study.26 Flow cytometry results suggest that both T cell subsets responded to antigen, but CD4+ T cells showed a more comprehensive and sustained cytokine response, while CD8+ T cell activation was largely restricted to IFN-γ expression. The most robust CD4+ T cell responses were observed at Day 7, aligning with the ELISpot findings. These results suggest that COVAC-2, particularly at the 25 µg dose, induced a focused antigen-specific cellular response, consistent with effective antiviral immunity.27,28 Antibody-mediated immunity also demonstrated a boosting effect despite high baseline titers, and although waning occurred, average antibody titers within the vaccinated groups were elevated above baseline at 6 months, as demonstrated by the GMFR values. The kinetics observed, rapid expansion followed by gradual contraction, are consistent with memory immune responses and support the potential of COVAC-2 to augment and extend existing immunity. Our findings align with recent studies evaluating recombinant protein vaccines as heterologous boosters.27 reported that a recombinant protein vaccine produced in Sf9 cells elicited significantly higher neutralizing antibody titers and enhanced Th1 responses compared to homologous boosting with no severe adverse events.28 found that the ReCOV recombinant protein booster provided comparable or superior cross-neutralization against variants and demonstrated good immune persistence. Furthermore,15 reported that NVX-CoV2373, when administered as a heterologous booster to adults primed with an adenovirus-based or mRNA-based COVID-19 vaccine induced significant pseudoviral neutralization titers and was associated with no safety concerns through study Day 91. These studies reinforce the safety and immunogenicity of recombinant protein vaccines and support their use in heterologous booster strategies. Importantly, our results also reflect the immune durability observed in Chen et al.29 who evaluated ZF2001, a recombinant protein vaccine formulated with aluminum hydroxide as the adjuvant, as a heterologous booster in Chinese adults previously vaccinated with an inactivated virus vaccine. Their study showed that neutralizing antibody titers peaked at Day 14 and declined gradually over six months, with no serious adverse events. As a booster vaccine candidate for COVID-19, COVAC-2 at the 25 µg dose demonstrated the most consistent and long lasting antibody and antigen-specific T-cell responses with some sustained immunity out to Day 180. This is particularly relevant given the global challenge of waning immunity following primary vaccination or natural infection. The observed kinetics, characterized by a rapid expansion of cytokine-producing T cells followed by a gradual contraction, are consistent with the expected behavior of memory T cells following booster immunization.30 While significant increases in antibody titers were observed for only select time points, a consistent trend toward enhanced humoral immunity was noted in the COVAC-2 boosted group compared to baseline and placebo. The limited number of statistically significant time points is likely due to the high baseline titers participants presented with at study entry, which reduced the relative magnitude of change detectable post-boost, which is a study limitation. Notably, antibody levels remained elevated up to six months post-boost, which further indicates that COVAC-2 may effectively augment pre-existing immunity, potentially extending the duration of protection. The GMFR observed in this study via ELISA and PNA may not be as high as those reported by some other recombinant proteins,27,28 but these studies had significantly lower baseline titers, which would impact the GMFR value. While a direct comparison of the post-boost neutralizing antibody titers cannot be made between this study and the data reported by Luo et al.27 and Yang et al.28 due to differences in assay units,28 did report binding antibody titers in BAU/mL, making this comparison possible. Boosting with COVAC-2 resulted in binding antibody titers equivalent to or better than titers obtained when individuals were boosted with either LYB001 or ZF2001. Similarly, while a direct comparison in neutralizing antibody titers cannot be made between this study and those induced by NVX-CoV2373 when administered as a booster due to differences in assay design and reported units, the GMFR reported by Lyke et al.15 were like those induced by COVAC-2. Overall, this suggests that COVAC-2 may be able to induce similar antibody titers as other, authorized, recombinant protein vaccines when administered as a heterologous booster. Comparative analyses of booster strategies have shown that heterologous regimens, especially those involving recombinant protein or mRNA platforms, often elicit stronger humoral and cellular immune responses than homologous regimens. For instance, a systematic review of 29 randomized clinical trials found that heterologous boosters, while not significantly reducing all-cause mortality or severe COVID-19 compared to homologous boosters, were associated with higher rates of non-serious adverse events and showed potential for broader immunogenicity.20 A study by Atmar et al.21 demonstrated that heterologous boosters increased neutralizing antibody titers more substantially than homologous boosters, with mRNA-based heterologous boosts showing particularly strong responses. In terms of T cell responses, heterologous regimens have been shown to induce more robust and diverse cellular immunity. A comparative study of T-cell repertoires revealed that heterologous boosting led to significantly higher numbers of SARS-CoV-2-specific T-cell rearrangements and elevated antibody titers compared to homologous boosting.22 Additionally, a review by Piano Mortari et al.31 emphasized that combining distinct vaccine platforms, such as adenoviral vectors and mRNA or protein subunits, can synergistically enhance both memory B cell and T cell responses. This study has limitations that should be considered when interpreting the findings. The most notable constraint was the incomplete cellular immunogenicity dataset, which limited the reliability of flow cytometry analyses and hindered assessment of long-term immune persistence. The antibody data set is also limited by the lack of data against any Variants of Concern. Additionally, high baseline antibody titers among participants reduced the detectable magnitude of humoral responses post-boost, resulting in fewer statistically significant changes. The heterogeneity in participants’ immunization histories introduced variability in pre-existing immunity, complicating the interpretation of vaccine-induced responses. The lack of systematic SARS-CoV-2 surveillance during the follow-up period has limited interpretation of the results for all groups as an unrecognized infection may be responsible for the increase in antibody titers observed in some participants on Days 90 and 180. However, late-onset vaccine-induced immunity cannot be ruled out. Although only a small number of participants received additional COVID-19 vaccinations during the study, and natural infection was not systematically tracked (for example through anti-N testing), these factors may have influenced immunogenicity outcomes, particularly in the placebo group. While these events likely had minimal impact, they underscore the importance of tracking intercurrent exposures in future studies. Finally, the study did not include an active comparator control, and as an early phase trial the study was not powered to evaluate efficacy or rare adverse events, limiting the generalizability of the results. Overall, these findings contribute to a growing body of evidence that suggests that a recombinant protein formulated with an oil-in-water adjuvant administered as a heterologous booster after receipt of mRNA vaccines may offer beneficial immunological outcomes and greater flexibility in deployment, and should continue to be evaluated to optimize ongoing protection against SARS-CoV-2 and address global disparities in vaccine access. Supplementary Material COVAC004_Supplementary_Figures_21May26.docx